NEW YORK - Theresa LaVallee joined the Parker Institute for Cancer Immunotherapy in 2017 and is currently VP of translational medicine and regulatory affairs. As part of the institute's efforts to bring precise and powerful immunotherapies to cancer patients, LaVallee and colleagues are on the front lines of both drug and biomarker development for a new class of therapies that are challenging the models of precision medicine established with the emergence of genomically targeted therapies.
Q&A: The Parker Institute's Theresa LaVallee on the Path Forward for Precision Immuno-Oncology
Premium
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.